Tagged with novartis

InFocus BACK TO HOME Patient Engagement in the Era of CAR-T BACK TO HOME Marc Boutin Global Head of Patient Engagement, novartis SHARE Share on twitter Share on linkedin “How are you today?” For patients, this question may be a challenge. Honest answers can stop a conversation straight away. I know…

Germany Christian Conrad outlines his role as patient engagement lead for Novartis Oncology in Germany, how individual patient interactions differ from those with advocacy groups, and the current situation for cancer patients eligible to receive Novartis’ CAR-T therapy in Germany.   There has been a big change in the last few…

USA Melanie Croce-Galis, RN, MPH explains the specificities of her work as patient engagement lead for Novartis Oncology in the US market, where significant disparities in patient access to information and to care throw up several challenges. Croce-Galis also outlines the work being done around CAR-T therapies and why integrating and…

China Portuguese national Isabel Afonso, a Novartis and Sandoz veteran of almost 20 years, has taken on a new role as general manager of Novartis’ highly strategic oncology franchise in China as of November 2021.   Since first joining the company back in 2002, Afonso held a variety of roles IT…

Global Karin Blumer, director of global patient engagement at Swiss giant Novartis, gives fascinating insights into the global patient advocacy landscape today and how Novartis interacts with it, the work being done on patient engagement and expectation management for the firm’s cutting-edge CAR-T therapies, and how a stronger patient voice can…

InFocus HOMEPAGE Patient Engagement in the Era of CAR-T In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers are seeking to become much more than just purveyors of pills and expand…

Global After 20 years, Novartis will no longer own one third of Roche’s shares after the two Swiss pharma giants agreed to a transaction worth USD 20.7 billion. While Roche touted the deal as the regaining of “full strategic flexibility”, Novartis argued that it was the right time to “monetize” its…

Singapore Angeline Ho gives an overview of the patient advocacy landscape in Asia-Pacific, why an Asian model of patient engagement – distinct from those in Europe and the US – needs to be developed, and how Novartis has been working with patients in the region around its CAR-T therapies.   It…

Denmark Data has been collected within Danish healthcare for more than 40 years, extending beyond the national patient registry to include a broad range of data points, from IVF to the birth registry, abortion, the weight and height of children, and much more. Danes tend to have a high level of…

Turkey In the world’s 18th largest market, recent pricing struggles have pushed some companies to revaluate their investment approach. Multinational organizations are complying with localization policies but are divided between having their own plant or partnering with a local CMO provider – although all of them appear to agree on one…

Denmark Danish pharma industry veteran Peter Drøidal highlights how he steered the Danish Novartis affiliate through the COVID-19 pandemic period, the strategy in place to navigate an increasingly challenging market access landscape, and the lessons that can be leveraged from the value-based agreement that Novartis was able to strike with the…

APAC The Asia-Pacific (APAC) region is home to around 1.44 billion people, over 60 percent of the world’s population, and a vast diversity of cultures, infrastructures, and economic development. Managing a life sciences company across multiple countries in this region can be extremely challenging but hugely important on both a human…